Early biomarkers of joint damage in rheumatoid and psoriatic arthritis.

Hdl Handle:
http://hdl.handle.net/10147/620657
Title:
Early biomarkers of joint damage in rheumatoid and psoriatic arthritis.
Authors:
Mc Ardle, Angela; Flatley, Brian; Pennington, Stephen R; FitzGerald, Oliver
Citation:
Early biomarkers of joint damage in rheumatoid and psoriatic arthritis. 2015, 17:141 Arthritis Res. Ther.
Publisher:
Springer
Journal:
Arthritis research & therapy
Issue Date:
2015
URI:
http://hdl.handle.net/10147/620657
DOI:
10.1186/s13075-015-0652-z
PubMed ID:
26028339
Additional Links:
http://arthritis-research.biomedcentral.com/articles/10.1186/s13075-015-0652-z
Abstract:
Joint destruction, as evidenced by radiographic findings, is a significant problem for patients suffering from rheumatoid arthritis and psoriatic arthritis. Inherently irreversible and frequently progressive, the process of joint damage begins at and even before the clinical onset of disease. However, rheumatoid and psoriatic arthropathies are heterogeneous in nature and not all patients progress to joint damage. It is therefore important to identify patients susceptible to joint destruction in order to initiate more aggressive treatment as soon as possible and thereby potentially prevent irreversible joint damage. At the same time, the high cost and potential side effects associated with aggressive treatment mean it is also important not to over treat patients and especially those who, even if left untreated, would not progress to joint destruction. It is therefore clear that a protein biomarker signature that could predict joint damage at an early stage would support more informed clinical decisions on the most appropriate treatment regimens for individual patients. Although many candidate biomarkers for rheumatoid and psoriatic arthritis have been reported in the literature, relatively few have reached clinical use and as a consequence the number of prognostic biomarkers used in rheumatology has remained relatively static for several years. It has become evident that a significant challenge in the transition of biomarker candidates to clinical diagnostic assays lies in the development of suitably robust biomarker assays, especially multiplexed assays, and their clinical validation in appropriate patient sample cohorts. Recent developments in mass spectrometry-based targeted quantitative protein measurements have transformed our ability to rapidly develop multiplexed protein biomarker assays. These advances are likely to have a significant impact on the validation of biomarkers in the future. In this review, we have comprehensively compiled a list of candidate biomarkers in rheumatoid and psoriatic arthritis, evaluated the evidence for their potential as biomarkers of bone (joint) damage, and outlined how mass spectrometry-based targeted and multiplexed measurement of candidate biomarker proteins is likely to accelerate their clinical validation and the development of clinical diagnostic tests.
Item Type:
Article
Language:
en
Keywords:
ARTHRITIS; MUSCULOSKELETAL DISORDERS
MeSH:
Arthritis, Psoriatic; Arthritis, Rheumatoid; Biomarkers; Disease Progression; Humans; Joints
ISSN:
1478-6362

Full metadata record

DC FieldValue Language
dc.contributor.authorMc Ardle, Angelaen
dc.contributor.authorFlatley, Brianen
dc.contributor.authorPennington, Stephen Ren
dc.contributor.authorFitzGerald, Oliveren
dc.date.accessioned2016-09-23T13:22:49Z-
dc.date.available2016-09-23T13:22:49Z-
dc.date.issued2015-
dc.identifier.citationEarly biomarkers of joint damage in rheumatoid and psoriatic arthritis. 2015, 17:141 Arthritis Res. Ther.en
dc.identifier.issn1478-6362-
dc.identifier.pmid26028339-
dc.identifier.doi10.1186/s13075-015-0652-z-
dc.identifier.urihttp://hdl.handle.net/10147/620657-
dc.description.abstractJoint destruction, as evidenced by radiographic findings, is a significant problem for patients suffering from rheumatoid arthritis and psoriatic arthritis. Inherently irreversible and frequently progressive, the process of joint damage begins at and even before the clinical onset of disease. However, rheumatoid and psoriatic arthropathies are heterogeneous in nature and not all patients progress to joint damage. It is therefore important to identify patients susceptible to joint destruction in order to initiate more aggressive treatment as soon as possible and thereby potentially prevent irreversible joint damage. At the same time, the high cost and potential side effects associated with aggressive treatment mean it is also important not to over treat patients and especially those who, even if left untreated, would not progress to joint destruction. It is therefore clear that a protein biomarker signature that could predict joint damage at an early stage would support more informed clinical decisions on the most appropriate treatment regimens for individual patients. Although many candidate biomarkers for rheumatoid and psoriatic arthritis have been reported in the literature, relatively few have reached clinical use and as a consequence the number of prognostic biomarkers used in rheumatology has remained relatively static for several years. It has become evident that a significant challenge in the transition of biomarker candidates to clinical diagnostic assays lies in the development of suitably robust biomarker assays, especially multiplexed assays, and their clinical validation in appropriate patient sample cohorts. Recent developments in mass spectrometry-based targeted quantitative protein measurements have transformed our ability to rapidly develop multiplexed protein biomarker assays. These advances are likely to have a significant impact on the validation of biomarkers in the future. In this review, we have comprehensively compiled a list of candidate biomarkers in rheumatoid and psoriatic arthritis, evaluated the evidence for their potential as biomarkers of bone (joint) damage, and outlined how mass spectrometry-based targeted and multiplexed measurement of candidate biomarker proteins is likely to accelerate their clinical validation and the development of clinical diagnostic tests.en
dc.language.isoenen
dc.publisherSpringeren
dc.relation.urlhttp://arthritis-research.biomedcentral.com/articles/10.1186/s13075-015-0652-zen
dc.rightsArchived with thanks to Arthritis research & therapyen
dc.subjectARTHRITISen
dc.subjectMUSCULOSKELETAL DISORDERSen
dc.subject.meshArthritis, Psoriatic-
dc.subject.meshArthritis, Rheumatoid-
dc.subject.meshBiomarkers-
dc.subject.meshDisease Progression-
dc.subject.meshHumans-
dc.subject.meshJoints-
dc.titleEarly biomarkers of joint damage in rheumatoid and psoriatic arthritis.en
dc.typeArticleen
dc.identifier.journalArthritis research & therapyen
dc.description.fundingOtheren
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.